Corrigendum to “Schisandrin A inhibits triple negative breast cancer cells by regulating Wnt/ER stress signaling pathway” [Biomed. Pharmacother. 115 (2019) 108922]
Main Authors: | Xiaohong Xu, Vinothakumar Rajamanicham, Sujing Xu, Zhoudi Liu, Tao Yan, Guang Liang, Guilong Guo, Huiping Zhou, Yi Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-05-01
|
Series: | Biomedicine & Pharmacotherapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222002542 |
Similar Items
-
Corrigendum to “Valproate, divalproex, valpromide: Are the differences in indications justified?” [Biomed. Pharmacother., 158 (2023) 114051]
by: Clément Delage, et al.
Published: (2023-12-01) -
Corrigendum to “Effects of oligonol on the submandibular gland in ovariectomized rats” [Biomed. Pharmacother. 141 (2021) 111897]
by: Jeong Hun Kim, et al.
Published: (2023-09-01) -
Corrigendum to “Steatosis in metabolic diseases: A focus on lipolysis and lipophagy” [Biomed. Pharmacother. 160 (2023) 114311]
by: Xingtao Zhao, et al.
Published: (2023-07-01) -
Corrigendum to “Insights into the implementation of Fibronectin 1 in the cartilage tissue engineering” [Biomed. Pharmacother. 148 (2022) 112782]
by: Murad Alahdal, et al.
Published: (2022-09-01) -
Corrigendum to “Tegaserod maleate exhibits antileukemic activity by targeting TRPM8” [Biomed. Pharmacother. 154 (2022) 113566]
by: Xiaoling Xie, et al.
Published: (2023-10-01)